The role of aurora A and polo-like kinases in high-risk lymphomas
High-risk lymphomas (HRLs) are associated with dismal outcomes and remain a therapeutic challenge. Recurrent genetic and molecular alterations, including c-myc expression and aurora A kinase (AAK) and polo-like kinase-1 (PLK1) activation, promote cell proliferation and contribute to the highly aggre...
Gespeichert in:
Veröffentlicht in: | Blood advances 2019-06, Vol.3 (11), p.1778-1787 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1787 |
---|---|
container_issue | 11 |
container_start_page | 1778 |
container_title | Blood advances |
container_volume | 3 |
creator | Murga-Zamalloa, Carlos Inamdar, Kedar V. Wilcox, Ryan A. |
description | High-risk lymphomas (HRLs) are associated with dismal outcomes and remain a therapeutic challenge. Recurrent genetic and molecular alterations, including c-myc expression and aurora A kinase (AAK) and polo-like kinase-1 (PLK1) activation, promote cell proliferation and contribute to the highly aggressive natural history associated with these lymphoproliferative disorders. In addition to its canonical targets regulating mitosis, the AAK/PLK1 axis directly regulates noncanonical targets, including c-myc. Recent studies demonstrate that HRLs, including T-cell lymphomas and many highly aggressive B-cell lymphomas, are dependent upon the AAK/PLK1 axis. Therefore, the AAK/PLK1 axis has emerged as an attractive therapeutic target in these lymphomas. In addition to reviewing these recent findings, we summarize the rationale for targeting AAK/PLK1 in high-risk and c-myc–driven lymphoproliferative disorders.
[Display omitted] |
doi_str_mv | 10.1182/bloodadvances.2019000232 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6560346</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952920307096</els_id><sourcerecordid>2340049792</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-4a27ce53358f624bc7aeec93f4efaeadd1a8bc7f0bf3a98563c18720ef3faf813</originalsourceid><addsrcrecordid>eNqFkU1PGzEQhq0KRBDlLyAfe1nw1374UimNaEGK1As9WxPvmHXjXad2Eol_j6tAaE492bKfeWY0LyGUs1vOO3G3CjH20O9hsphvBeOaMSak-EQuhWplpWvZnh3vQs_Idc6_C8PbRtZaXJCZLKJG1OqSzJ8GpCkGpNFR2KWYgM4pTD3dxBCr4NdI136CjJn6iQ7-eaiSz2saXsbNEEfIn8m5g5Dx-u28Ir--3z8tHqrlzx-Pi_mysqrV20qBaC3WUtada4Ra2RYQrZZOoQOEvufQlUfHVk6C7upGWt61gqGTDlzH5RX5evBudqsRe4vTNkEwm-RHSC8mgjenP5MfzHPcm6ZumFRNEXx5E6T4Z4d5a0afLYYAE8ZdNkIqxpRutShod0BtijkndMc2nJm_IZiTEMxHCKX05t8xj4XvKy_AtwOAZVl7j8lk67Foep_Qbk0f_f-7vAL3_J88</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2340049792</pqid></control><display><type>article</type><title>The role of aurora A and polo-like kinases in high-risk lymphomas</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Murga-Zamalloa, Carlos ; Inamdar, Kedar V. ; Wilcox, Ryan A.</creator><creatorcontrib>Murga-Zamalloa, Carlos ; Inamdar, Kedar V. ; Wilcox, Ryan A.</creatorcontrib><description>High-risk lymphomas (HRLs) are associated with dismal outcomes and remain a therapeutic challenge. Recurrent genetic and molecular alterations, including c-myc expression and aurora A kinase (AAK) and polo-like kinase-1 (PLK1) activation, promote cell proliferation and contribute to the highly aggressive natural history associated with these lymphoproliferative disorders. In addition to its canonical targets regulating mitosis, the AAK/PLK1 axis directly regulates noncanonical targets, including c-myc. Recent studies demonstrate that HRLs, including T-cell lymphomas and many highly aggressive B-cell lymphomas, are dependent upon the AAK/PLK1 axis. Therefore, the AAK/PLK1 axis has emerged as an attractive therapeutic target in these lymphomas. In addition to reviewing these recent findings, we summarize the rationale for targeting AAK/PLK1 in high-risk and c-myc–driven lymphoproliferative disorders.
[Display omitted]</description><identifier>ISSN: 2473-9529</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2019000232</identifier><identifier>PMID: 31186254</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Aurora Kinase A - metabolism ; Cell Cycle Proteins - metabolism ; Humans ; Lymphoma, B-Cell - enzymology ; Lymphoma, B-Cell - pathology ; Lymphoma, B-Cell - therapy ; Lymphoma, T-Cell - enzymology ; Lymphoma, T-Cell - pathology ; Lymphoma, T-Cell - therapy ; Polo-Like Kinase 1 ; Protein Serine-Threonine Kinases - metabolism ; Proto-Oncogene Proteins - metabolism ; Proto-Oncogene Proteins c-myc - metabolism ; Review ; Risk Factors ; Signal Transduction</subject><ispartof>Blood advances, 2019-06, Vol.3 (11), p.1778-1787</ispartof><rights>2019 American Society of Hematology</rights><rights>2019 by The American Society of Hematology.</rights><rights>2019 by The American Society of Hematology 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-4a27ce53358f624bc7aeec93f4efaeadd1a8bc7f0bf3a98563c18720ef3faf813</citedby><cites>FETCH-LOGICAL-c479t-4a27ce53358f624bc7aeec93f4efaeadd1a8bc7f0bf3a98563c18720ef3faf813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560346/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560346/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31186254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murga-Zamalloa, Carlos</creatorcontrib><creatorcontrib>Inamdar, Kedar V.</creatorcontrib><creatorcontrib>Wilcox, Ryan A.</creatorcontrib><title>The role of aurora A and polo-like kinases in high-risk lymphomas</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>High-risk lymphomas (HRLs) are associated with dismal outcomes and remain a therapeutic challenge. Recurrent genetic and molecular alterations, including c-myc expression and aurora A kinase (AAK) and polo-like kinase-1 (PLK1) activation, promote cell proliferation and contribute to the highly aggressive natural history associated with these lymphoproliferative disorders. In addition to its canonical targets regulating mitosis, the AAK/PLK1 axis directly regulates noncanonical targets, including c-myc. Recent studies demonstrate that HRLs, including T-cell lymphomas and many highly aggressive B-cell lymphomas, are dependent upon the AAK/PLK1 axis. Therefore, the AAK/PLK1 axis has emerged as an attractive therapeutic target in these lymphomas. In addition to reviewing these recent findings, we summarize the rationale for targeting AAK/PLK1 in high-risk and c-myc–driven lymphoproliferative disorders.
[Display omitted]</description><subject>Animals</subject><subject>Aurora Kinase A - metabolism</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>Humans</subject><subject>Lymphoma, B-Cell - enzymology</subject><subject>Lymphoma, B-Cell - pathology</subject><subject>Lymphoma, B-Cell - therapy</subject><subject>Lymphoma, T-Cell - enzymology</subject><subject>Lymphoma, T-Cell - pathology</subject><subject>Lymphoma, T-Cell - therapy</subject><subject>Polo-Like Kinase 1</subject><subject>Protein Serine-Threonine Kinases - metabolism</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Proto-Oncogene Proteins c-myc - metabolism</subject><subject>Review</subject><subject>Risk Factors</subject><subject>Signal Transduction</subject><issn>2473-9529</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1PGzEQhq0KRBDlLyAfe1nw1374UimNaEGK1As9WxPvmHXjXad2Eol_j6tAaE492bKfeWY0LyGUs1vOO3G3CjH20O9hsphvBeOaMSak-EQuhWplpWvZnh3vQs_Idc6_C8PbRtZaXJCZLKJG1OqSzJ8GpCkGpNFR2KWYgM4pTD3dxBCr4NdI136CjJn6iQ7-eaiSz2saXsbNEEfIn8m5g5Dx-u28Ir--3z8tHqrlzx-Pi_mysqrV20qBaC3WUtada4Ra2RYQrZZOoQOEvufQlUfHVk6C7upGWt61gqGTDlzH5RX5evBudqsRe4vTNkEwm-RHSC8mgjenP5MfzHPcm6ZumFRNEXx5E6T4Z4d5a0afLYYAE8ZdNkIqxpRutShod0BtijkndMc2nJm_IZiTEMxHCKX05t8xj4XvKy_AtwOAZVl7j8lk67Foep_Qbk0f_f-7vAL3_J88</recordid><startdate>20190611</startdate><enddate>20190611</enddate><creator>Murga-Zamalloa, Carlos</creator><creator>Inamdar, Kedar V.</creator><creator>Wilcox, Ryan A.</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190611</creationdate><title>The role of aurora A and polo-like kinases in high-risk lymphomas</title><author>Murga-Zamalloa, Carlos ; Inamdar, Kedar V. ; Wilcox, Ryan A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-4a27ce53358f624bc7aeec93f4efaeadd1a8bc7f0bf3a98563c18720ef3faf813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Aurora Kinase A - metabolism</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>Humans</topic><topic>Lymphoma, B-Cell - enzymology</topic><topic>Lymphoma, B-Cell - pathology</topic><topic>Lymphoma, B-Cell - therapy</topic><topic>Lymphoma, T-Cell - enzymology</topic><topic>Lymphoma, T-Cell - pathology</topic><topic>Lymphoma, T-Cell - therapy</topic><topic>Polo-Like Kinase 1</topic><topic>Protein Serine-Threonine Kinases - metabolism</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Proto-Oncogene Proteins c-myc - metabolism</topic><topic>Review</topic><topic>Risk Factors</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murga-Zamalloa, Carlos</creatorcontrib><creatorcontrib>Inamdar, Kedar V.</creatorcontrib><creatorcontrib>Wilcox, Ryan A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murga-Zamalloa, Carlos</au><au>Inamdar, Kedar V.</au><au>Wilcox, Ryan A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of aurora A and polo-like kinases in high-risk lymphomas</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2019-06-11</date><risdate>2019</risdate><volume>3</volume><issue>11</issue><spage>1778</spage><epage>1787</epage><pages>1778-1787</pages><issn>2473-9529</issn><eissn>2473-9537</eissn><abstract>High-risk lymphomas (HRLs) are associated with dismal outcomes and remain a therapeutic challenge. Recurrent genetic and molecular alterations, including c-myc expression and aurora A kinase (AAK) and polo-like kinase-1 (PLK1) activation, promote cell proliferation and contribute to the highly aggressive natural history associated with these lymphoproliferative disorders. In addition to its canonical targets regulating mitosis, the AAK/PLK1 axis directly regulates noncanonical targets, including c-myc. Recent studies demonstrate that HRLs, including T-cell lymphomas and many highly aggressive B-cell lymphomas, are dependent upon the AAK/PLK1 axis. Therefore, the AAK/PLK1 axis has emerged as an attractive therapeutic target in these lymphomas. In addition to reviewing these recent findings, we summarize the rationale for targeting AAK/PLK1 in high-risk and c-myc–driven lymphoproliferative disorders.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31186254</pmid><doi>10.1182/bloodadvances.2019000232</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2473-9529 |
ispartof | Blood advances, 2019-06, Vol.3 (11), p.1778-1787 |
issn | 2473-9529 2473-9537 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6560346 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Animals Aurora Kinase A - metabolism Cell Cycle Proteins - metabolism Humans Lymphoma, B-Cell - enzymology Lymphoma, B-Cell - pathology Lymphoma, B-Cell - therapy Lymphoma, T-Cell - enzymology Lymphoma, T-Cell - pathology Lymphoma, T-Cell - therapy Polo-Like Kinase 1 Protein Serine-Threonine Kinases - metabolism Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins c-myc - metabolism Review Risk Factors Signal Transduction |
title | The role of aurora A and polo-like kinases in high-risk lymphomas |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A17%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20aurora%20A%20and%20polo-like%20kinases%20in%20high-risk%20lymphomas&rft.jtitle=Blood%20advances&rft.au=Murga-Zamalloa,%20Carlos&rft.date=2019-06-11&rft.volume=3&rft.issue=11&rft.spage=1778&rft.epage=1787&rft.pages=1778-1787&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2019000232&rft_dat=%3Cproquest_pubme%3E2340049792%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2340049792&rft_id=info:pmid/31186254&rft_els_id=S2473952920307096&rfr_iscdi=true |